COVID Supplement NIAID DAIT CLINICAL PRODUCTS CENTER (CPC)

根据合同，临床产品中心为所有dait资助和/或赞助的临床研究项目和其他niaid资助的临床试验提供研究产品服务。需要支持的研究包括广泛的免疫介导和罕见疾病，包括：(i)哮喘和过敏性疾病；（ii）自身免疫性疾病；实体器官、组织和细胞移植中免疫介导的排斥反应；（四）基础科学研究（类阿片疫苗研究）。此外，根据需要进行传染病治疗（如sars - cov -2）、预防和其他疫苗研究的临床试验。待研究的试验产品包括表一至表六的药物制剂、生物制剂、作为研究干预措施的食品和其他制剂。

The Clinical Product Center under contract, provides Investigational Product Services for all DAIT-funded and/or sponsored clinical research programs and other NIAID-funded clinical trials as needed. Studies to be supported encompass a broad range of immune-mediated & rare diseases, including: (i) asthma and allergic diseases; (ii) autoimmune disorders; (iii) immune-mediated rejection in solid organ, tissue and cell transplantation; and (iv) (v) Basic Science studies (Opioid Vaccine studies). Additionally, and on an as-needed basis, clinical trials of infectious disease treatment (i.e.SARS-CoV-2), prevention and other vaccine studies. Investigational Products to be studied include schedule I through VI pharmaceutical agents, biologics, foods as study interventions, and other agents.